Meclofenoxate therapy in tardive dyskinesia: a preliminary report.
Tardive dyskinesia seems to occur as a result of diminished cholinergic and enhanced dopaminergic activity in the striatum. Meclofenoxate has been shown to increase cerebral cholinergic activity. To ameliorate the tardive dyskinesia, meclofenoxate was given orally, 600-1200 mg/day, for 6-12 weeks. The effects of the drug were evaluated by scoring the degree of involuntary movement. Among 11 subjects with tardive dyskinesia or dystonia, 4 improved markedly, 1 moderately, 2 slightly, and there was no improvement in 4. One patient with subacute oral dyskinesia, induced by administration of neuroleptics for 1 month, improved markedly. The possibility that meclofenoxate may be effective in dealing with dyskinesias that are induced by neuroleptics warrants further attention.
Izumi
K
K
Tominaga
H
H
Koja
T
T
Nomoto
M
M
Shimizu
T
T
Sonoda
H
H
Imamura
K
K
Igata
A
A
Fukuda
T
T
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001714:Bipolar Disorder / Q000188:drug therapy*; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004576:Electromyography; D005260:Female; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D002504:Meclofenoxate / Q000627:therapeutic use*; D008875:Middle Aged; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D006016:Glycolates; D002504:Meclofenoxate